Interleukin-1 (IL-1) inhibitors : anakinra, rilonacept, and canakinumab

Kevin D. Pile; Garry G. Graham; Stephen M. Mahler

doi:10.1007/978-3-7643-8550-7_29

Interleukin-1 (IL-1) inhibitors : anakinra, rilonacept, and canakinumab

Kevin D. Pile, Garry G. Graham, Stephen M. Mahler

Western Sydney University

Research output: Chapter in Book / Conference Paper › Chapter

Abstract

![CDATA[Inhibitors of interleukin-1 (IL-1) are proteins which decrease the actions of the inflammatory cytokine, IL-1. There are two general mechanisms of IL-1 inhibitors: binding to the IL-1 receptor (anakinra) or binding directly to IL-1 (rilonacept and canakinumab). They are members of a general class termed biological disease-modifying antirheumatic drugs (bDMARDs). They are not classified as slow-acting antirheumatic drugs (SAARDs) because they are considered to have more specific and rapidly developing actions. Clinically, the major IL-1 inhibitor is anakinra.]]

Original language	English
Title of host publication	Compendium of Inflammatory Diseases
Editors	Michael J. Parnham
Place of Publication	Switzerland
Publisher	Springer
Pages	666-670
Number of pages	5
ISBN (Electronic)	9783764385507
ISBN (Print)	9783764385309
DOIs	https://doi.org/10.1007/978-3-7643-8550-7_29
Publication status	Published - 2016

Keywords

interleukin-1
antirheumatic agents

Access to Document

10.1007/978-3-7643-8550-7_29

Cite this

@inbook{9ed20cc48b124dcfa3ac5c9b3782dcb4,

title = "Interleukin-1 (IL-1) inhibitors : anakinra, rilonacept, and canakinumab",

abstract = "![CDATA[Inhibitors of interleukin-1 (IL-1) are proteins which decrease the actions of the inflammatory cytokine, IL-1. There are two general mechanisms of IL-1 inhibitors: binding to the IL-1 receptor (anakinra) or binding directly to IL-1 (rilonacept and canakinumab). They are members of a general class termed biological disease-modifying antirheumatic drugs (bDMARDs). They are not classified as slow-acting antirheumatic drugs (SAARDs) because they are considered to have more specific and rapidly developing actions. Clinically, the major IL-1 inhibitor is anakinra.]]",

keywords = "interleukin-1, antirheumatic agents",

author = "Pile, {Kevin D.} and Graham, {Garry G.} and Mahler, {Stephen M.}",

year = "2016",

doi = "10.1007/978-3-7643-8550-7_29",

language = "English",

isbn = "9783764385309",

pages = "666--670",

editor = "Parnham, {Michael J.}",

booktitle = "Compendium of Inflammatory Diseases",

publisher = "Springer",

}

TY - CHAP

T1 - Interleukin-1 (IL-1) inhibitors : anakinra, rilonacept, and canakinumab

AU - Pile, Kevin D.

AU - Graham, Garry G.

AU - Mahler, Stephen M.

PY - 2016

Y1 - 2016

N2 - ![CDATA[Inhibitors of interleukin-1 (IL-1) are proteins which decrease the actions of the inflammatory cytokine, IL-1. There are two general mechanisms of IL-1 inhibitors: binding to the IL-1 receptor (anakinra) or binding directly to IL-1 (rilonacept and canakinumab). They are members of a general class termed biological disease-modifying antirheumatic drugs (bDMARDs). They are not classified as slow-acting antirheumatic drugs (SAARDs) because they are considered to have more specific and rapidly developing actions. Clinically, the major IL-1 inhibitor is anakinra.]]

AB - ![CDATA[Inhibitors of interleukin-1 (IL-1) are proteins which decrease the actions of the inflammatory cytokine, IL-1. There are two general mechanisms of IL-1 inhibitors: binding to the IL-1 receptor (anakinra) or binding directly to IL-1 (rilonacept and canakinumab). They are members of a general class termed biological disease-modifying antirheumatic drugs (bDMARDs). They are not classified as slow-acting antirheumatic drugs (SAARDs) because they are considered to have more specific and rapidly developing actions. Clinically, the major IL-1 inhibitor is anakinra.]]

KW - interleukin-1

KW - antirheumatic agents

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:40018

U2 - 10.1007/978-3-7643-8550-7_29

DO - 10.1007/978-3-7643-8550-7_29

M3 - Chapter

SN - 9783764385309

SP - 666

EP - 670

BT - Compendium of Inflammatory Diseases

A2 - Parnham, Michael J.

PB - Springer

CY - Switzerland

ER -

Interleukin-1 (IL-1) inhibitors : anakinra, rilonacept, and canakinumab

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this